1. HBW Insight
  2. >>Wellness
  3. >>Business

Perrigo Pivots To 'Self Care' For 'Massive Opportunity' Beyond OTC Drugs

 
• By Malcolm Spicer

Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.

OTC drug private label giant Perrigo Co. PLC will change its focus from health care to "self care" and compete outside its core sector to solve its revenue problems, says recently appointed CEO Murray Kessler.

During Perrigo's 2018 third-quarter earnings briefing Nov. 8, Kessler also said the firm's Rx generics business will see some changes even as Perrigo still looks to sell it or spin it off

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 
• By Malcolm Spicer

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

More from Wellness

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

NAD Asks FTC To Pull Bandage Off Firm’s Plan To Exhaust Inventory Using ‘2X Faster Healing’ Claim

 
• By Malcolm Spicer

After National Advertising Division attorneys, in a review prompted by a challenge by Band-Aid line marketer Kenvue, recommended ASO LLV cease use of its “up to 2x faster healing” claim, they determined the firm had not fully complied.